Prominent Harvard professor in the hunt for $100M to back his anti-aging play

John Carroll

Editor & Founder

Harvard’s David Sinclair has set out to raise $100 million for his anti-aging startup Life Biosciences. And he has some prominent names among the backers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Prominent Harvard professor in the hunt for $100M to back his anti-aging play

John Carroll

Editor & Founder

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Promi­nent Har­vard pro­fes­sor in the hunt for $100M to back his an­ti-ag­ing play

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Prominent Harvard professor in the hunt for $100M to back his anti-aging play

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life